Clinical trials: Placebo Group
Atopic Dermatitis
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
- Trial name
- NCT00125333
- Testing
- NF-kappaB Decoy
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- Anesiva, Inc.
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Diabetic Macular Edema
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of…
- Trial name
- NCT01319487
- Testing
- 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Fovea Pharmaceuticals SA
Acute Blunt Soft Tissue Injuries/Contusions
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
The purpose of this study is to evaluate the efficacy of DSG 1% compared with placebo applied four times a day in subjects with acute blunt soft tissue injuries/contusions of the limbs
- Trial name
- NCT01272947
- Testing
- Diclofenac sodium
- Where
- 6 sites in Germany
- Volunteers
- 204 people
- Sponsor
- Novartis
Overactive Bladder
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets…
- Trial name
- VEL-2001 (NCT03594058)
- Testing
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose
- Where
- 77 sites in United States
- Volunteers
- 1,413 people
- Sponsor
- Velicept Therapeutics, Inc.
Major Depressive Disorder
Major Depressive Disorder With Mixed Features
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
- Trial name
- RESOLVE2 (NCT01423240)
- Testing
- Lurasidone 20 mg, Lurasidone 60 mg
- Where
- 27 sites in United States
- Sponsor
- Sumitomo Pharma America, Inc.
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
This is a study of experimental medication BMS-986263 in adult patients with advanced hepatic fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after the patient is cured of hepatitis C (an…
- Trial name
- NCT03420768
- Testing
- BMS-986263
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as…
- Trial name
- NCT07612150
- Testing
- TML-6
- Volunteers
- 210 people
- Sponsor
- Merry Life Biomedical Co., Ltd.
Anaemia
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease.
- Trial name
- NCT02689206
- Testing
- GSK1278863
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
Study Evaluating the Effects of Avanafil on Semen Parameters
The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.
- Trial name
- NCT01768676
- Testing
- avanafil
- Where
- 15 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Acquired Bleeding Disorder, Trauma
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma Please note that this trial and…
- Trial name
- NCT00323570
- Testing
- activated recombinant human factor VII
- Where
- 42 sites in United States
- Sponsor
- Novo Nordisk A/S
Bipolar I Disorder
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder.
- Trial name
- NCT00107731
- Testing
- quetiapine fumarate, lithium, divalproex
- Where
- 166 sites in United States, Australia and 16 more
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis (SAR)
Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic Rhinitis (SAR).
- Trial name
- GSP 301-305 (NCT03463031)
- Testing
- GSP 301 NS
- Where
- 32 sites in United States
- Volunteers
- 446 people
- Sponsor
- Glenmark Specialty S.A.
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
The cornea forms our "window to the world". Hence, its transparency is of utmost importance for vision. Corneal endothelium plays a central role in the maintenance of a transparent corneal stroma.
- Conditions
- Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Corneal Endothelial Dystrophy, Corneal Endothelial Cell Loss
- Trial name
- NCT03575130
- Testing
- Ripasudil eye drops, Optive eye drops, Descemetorhexis
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Healthy Volunteers
AZD5423 Single Ascending Dose Study
The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5423 following single ascending dose administrations in healthy male subjects.
- Trial name
- NCT00963183
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers
Study to evaluate safety, tolerability, and pharmacokinetics of BI 1744 CL in healthy Japanese male volunteers.
- Trial name
- NCT02172105
- Testing
- BI 1744 CL
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Early Stage Parkinson Disease
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD.
- Trial name
- NCT00335166
- Testing
- Pardaprunox, pramipexole
- Where
- 89 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Solvay Pharmaceuticals
Influenza
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
- Trial name
- NCT04439695
- Testing
- Low dose, Intermediate dose, High dose
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Overweight, Obesity
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated administration of GSP3, an investigational product, on body weight.
- Trial name
- FLOW (NCT03008954)
- Testing
- GSP3, Avicel (modified Cellulose)
- Where
- 5 sites in Czechia, Denmark and 1 more
- Volunteers
- 128 people
- Sponsor
- Gelesis, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.